Atrial Natriuretic Peptide (ANP), Rat: Vasodilator Peptide for Blood Pressure Regulation & Cardiovascular Research

Executive Summary: Atrial Natriuretic Peptide (ANP), rat, is a 28-amino acid hormone with the molecular formula C₄₉H₈₄N₂₀O₁₅S and a molecular weight of 1225.38, synthesized by atrial myocytes in response to cardiac stimuli (APExBIO). ANP acts as a potent vasodilator and natriuretic agent, lowering blood pressure by promoting renal sodium and water excretion (angiotensin-ii.com). Its purity (95.92%) is confirmed by HPLC and mass spectrometry, enabling reliable use in cardiovascular, renal, and adipose metabolism research. ANP's mechanistic actions extend to the modulation of sympathetic nervous system activity and inhibition of the renin-angiotensin-aldosterone system (RAAS) (bnp1-32.com). The peptide is widely used in rat models to elucidate the molecular basis of blood pressure homeostasis and natriuresis (Zhang et al. 2022).

Biological Rationale

Atrial Natriuretic Peptide (ANP) is primarily synthesized, stored, and secreted by atrial myocytes in mammalian hearts. Its release is triggered by atrial distension, elevated blood volume, angiotensin II, endothelin, and sympathetic nervous system activation (bnp1-32.com). ANP is evolutionarily conserved in rats and humans, and its primary sequence in the rat is H-Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-OH. In rats, ANP functions as a critical regulator of cardiovascular homeostasis by inducing vasodilation, promoting natriuresis (excretion of sodium in urine), and diuresis (excretion of water in urine) (angiotensin-ii.com). These effects collectively lower systemic blood pressure and reduce cardiac preload and afterload. ANP also influences adipose tissue metabolism, facilitating lipolysis and modulating adiponectin secretion (Zhang et al. 2022).

Mechanism of Action of Atrial Natriuretic Peptide (ANP), rat

Upon release, ANP binds to natriuretic peptide receptor-A (NPR-A), a membrane-bound guanylyl cyclase. This interaction catalyzes the conversion of GTP to cyclic GMP (cGMP), a secondary messenger that triggers downstream signaling cascades. Elevated cGMP levels mediate vasodilation in vascular smooth muscle cells and increase glomerular filtration rate (GFR) in the kidney (sitagliptinphosphate.com). In renal tissue, ANP inhibits sodium reabsorption in the distal convoluted tubule and collecting duct, enhancing natriuresis. ANP also suppresses the renin-angiotensin-aldosterone system (RAAS), reducing aldosterone-mediated sodium retention. In adipose tissue, ANP promotes lipolysis and increases adiponectin secretion, contributing to the regulation of metabolic homeostasis (Zhang et al. 2022).

Evidence & Benchmarks

• ANP administration in rat models produces a dose-dependent reduction in systolic blood pressure within 10–30 minutes post-injection, measured at 25°C in saline buffer (Zhang et al., https://doi.org/10.21203/rs.3.rs-2117207/v1).
• Purity of the APExBIO A1009 product is 95.92% as confirmed by HPLC and MS under standard analytical conditions (APExBIO).
• ANP is soluble at ≥122.5 mg/mL in DMSO and ≥43.5 mg/mL in water, but insoluble in ethanol at room temperature (endothelin-1.com).
• ANP enhances natriuresis and diuresis in Sprague Dawley rats, with a significant increase in urinary sodium excretion (measured in mmol/L, pH 7.4, 37°C) over 2–4 hours (angiotensin-ii.com).
• In vitro, ANP stimulates cGMP production in cultured vascular smooth muscle cells at concentrations ≥1 nM, assessed by ELISA (bnp1-32.com).

Applications, Limits & Misconceptions

APExBIO’s Atrial Natriuretic Peptide (ANP), rat, is validated in cardiovascular, renal, and metabolic research. It is used to probe natriuresis mechanisms, test blood pressure regulation interventions, and investigate adipose tissue metabolism. The product’s high purity and batch consistency enable quantitative, reproducible workflows (sitagliptinphosphate.com). This article extends earlier work by integrating mechanistic detail and updated benchmarks, providing a translational context not found in previous summaries (angiotensin-ii.com).

Common Pitfalls or Misconceptions

• ANP is not effective as an antihypertensive in models with impaired NPR-A or cGMP signaling.
• The peptide is insoluble in ethanol and should not be reconstituted in this solvent.
• Long-term storage of reconstituted solutions at room temperature leads to rapid degradation; fresh preparation is essential.
• ANP does not directly modulate neuroinflammation—effects on the CNS are secondary to peripheral actions and require further research (Zhang et al. 2022).
• It is not a substitute for chronic antihypertensive therapy in clinical settings; use is limited to experimental models.

Workflow Integration & Parameters

APExBIO's Atrial Natriuretic Peptide (ANP), rat (SKU: A1009), is supplied as a solid to be stored at -20°C. For in vivo experiments, dissolve at concentrations ≥122.5 mg/mL in DMSO or ≥43.5 mg/mL in water; avoid ethanol due to insolubility (product page). Use freshly prepared solutions for maximal activity. In typical rat studies, administer intraperitoneally at 1–30 μg/kg, monitoring blood pressure, urine volume, and electrolyte excretion over 2–24 hours. Analytical confirmation of peptide identity and purity by HPLC and mass spectrometry is recommended for each batch.

For advanced protocols and troubleshooting, see this applied workflow article, which focuses on practical issues in blood pressure and renal physiology studies. This article builds on that resource by providing updated solubility, mechanistic, and purity data, as well as integrated evidence from recent literature. For mechanistic innovations in neuroimmune research and adipose metabolism, see this perspective, which this dossier updates with new quantitative benchmarks and experimental design tips.

Conclusion & Outlook

Atrial Natriuretic Peptide (ANP), rat, is a validated vasodilator and natriuretic peptide essential for blood pressure regulation, natriuresis mechanism study, and adipose tissue metabolism regulation. With 95.92% purity and robust solubility, APExBIO’s A1009 product supports reproducible, quantitative experimentation in cardiovascular and renal research. As translational models evolve, ANP remains a pivotal tool for dissecting homeostatic and metabolic regulatory networks in rats. For product details and ordering, see the A1009 kit.